Topics
May/June 2026 | Letter to the Editors - Online Exclusive
Beyond One-Size-Fits-All: The Move Toward Personalized Vitreoretinal Therapy
By calculating the vitreous volume exact, clinicians can treat eyes with greater precision.
Andreas F. Borkenstein, MD
November 19, 2026
FDA Grants Rare Disease Evidence Principles Designation to NanoRetinal’s NAR-001 for Inherited Retinal Dystrophy
Foundation Fighting Blindness Receives $1 Million Commitment to Advance Gene-Agnostic Retinal Disease Therapies
November 17, 2026
MacuMira Receives CE Mark Certification for Retinal Microcurrent Stimulation Device to Treat Dry AMD
November 16, 2026
Johnson & Johnson to Acquire Ollin Biosciences for $2.2 Billion, Advancing Retinal Disease Pipeline
October 2026 Insert
Editorially Independent Content, Supported With Advertising From Asetllas
Editorially independent supported by Abbvie and Regenxbio
Supported by Zeiss
Free Print Subscription
Email Newsletter
Conference Calendar